Screener
Icahn Enterprises IEP Pharma — D&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Icahn Enterprises’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-090605
| Line item | Investment | Energy | Automotive | Food Packaging | Real Estate | Home Fashion | Pharma | Holding Company | Consolidated |
|---|---|---|---|---|---|---|---|---|---|
| (Loss) income before income tax benefit | (312) | 40 | (14) | (5) | (1) | (2) | (7) | (85) | (386) |
| Income tax (expense) benefit | — | (6) | 4 | (1) | — | — | — | 1 | (2) |
| Net (loss) income | (312) | 34 | (10) | (6) | (1) | (2) | (7) | (84) | (388) |
| Less: net (loss) income attributable to non-controlling interests | (74) | 41 | — | — | — | — | — | — | (33) |
| Net loss attributable to Icahn Enterprises | $(238) | $(7) | $(10) | $(6) | $(1) | $(2) | $(7) | $(84) | $(355) |
| Supplemental information: | |||||||||
| Capital expenditures | — | $43 | $21 | $7 | $9 | — | — | — | $80 |
| Depreciation and amortization | — | $95 | $12 | $5 | $8 | $2 | $2 | — | $124 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Icahn Enterprises's pharma — D&A?
- Icahn Enterprises (IEP) reported pharma — D&A of $2M in Q2 2026.
- How has Icahn Enterprises's pharma — D&A changed year-over-year?
- Icahn Enterprises's pharma — D&A decreased by 71.4% year-over-year, from $7M to $2M.
- What is the long-term trend for Icahn Enterprises's pharma — D&A?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — D&A has grown at a 0.0% compound annual growth rate (CAGR), from $28M to $28M.
- What does pharma — D&A mean?
- Represents the non-cash allocation of costs for tangible and intangible assets over their useful lives within the Pharma segment. This metric highlights the capital intensity of the business and the ongoing investment required to maintain operational capacity. It is a critical component for calculating cash flow metrics and understanding asset utilization.
Ask your AI about Icahn Enterprises's pharma — d&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude